Literature DB >> 20876525

Proinflammatory signals and the loss of lymphatic vessel hyaluronan receptor-1 (LYVE-1) in the early pathogenesis of laminin alpha2-deficient skeletal muscle.

Katherine E Wardrop1, Janice A Dominov.   

Abstract

Congenital muscular dystrophy type 1A, a severe neuromuscular disease characterized by early-onset muscle weakness and degeneration, is caused by insufficient levels of laminin α2 (LAMA2) in the basal lamina surrounding muscle fibers and other cells. A better understanding of the molecular mechanisms leading to muscle loss is needed to develop therapeutic interventions for this disease. Here, the authors show that inflammation is an early feature of pathogenesis in Lama2-deficient mouse muscle, indicated by elevated expression of tenascin C in the endomysium around muscle fibers, infiltration of macrophages, and induction of the inflammatory cytokines tumor necrosis factor α (TNFα) and IL-1β. In addition, the expression of lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), a specific marker for lymphatic vessel endothelial cells, is dramatically reduced early in Lama2-deficient muscle pathogenesis. LYVE-1 expression, which is inhibited by TNFα, is also decreased in muscles undergoing degeneration due to dystrophin deficiency and cardiotoxin damage. LYVE-1 expression thus provides a useful biomarker to monitor the onset of muscle pathogenesis, likely serving as an indicator of inflammatory signals present in muscles. Together, the data show that inflammatory pathways are activated in the earliest stages of Lama2-deficient disease progression and could play a role in early muscle degeneration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20876525      PMCID: PMC3201133          DOI: 10.1369/jhc.2010.956672

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  53 in total

1.  Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy.

Authors:  Y Miyagoe; K Hanaoka; I Nonaka; M Hayasaka; Y Nabeshima; K Arahata; Y Nabeshima; S Takeda
Journal:  FEBS Lett       Date:  1997-09-22       Impact factor: 4.124

2.  The pathologic spectrum of merosin deficiency.

Authors:  R E Mrak
Journal:  J Child Neurol       Date:  1998-10       Impact factor: 1.987

3.  Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C.

Authors:  A Ristimäki; K Narko; B Enholm; V Joukov; K Alitalo
Journal:  J Biol Chem       Date:  1998-04-03       Impact factor: 5.157

4.  Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy.

Authors:  E Pegoraro; P Mancias; S H Swerdlow; R B Raikow; C Garcia; H Marks; T Crawford; V Carver; B Di Cianno; E P Hoffman
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

5.  Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene.

Authors:  H Xu; X R Wu; U M Wewer; E Engvall
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

6.  Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models.

Authors:  W Kuang; H Xu; P H Vachon; L Liu; F Loechel; U M Wewer; E Engvall
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

7.  Tenascin is a useful marker in the diagnosis of inflammatory myopathies.

Authors:  W Müller-Felber; M Toepfer; T Müller; J Müller-Höcker; P Fischer; H Lochmüller; D Pongratz
Journal:  Eur J Med Res       Date:  1998-06-17       Impact factor: 2.175

8.  Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy.

Authors:  A Helbling-Leclerc; X Zhang; H Topaloglu; C Cruaud; F Tesson; J Weissenbach; F M Tomé; K Schwartz; M Fardeau; K Tryggvason
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

9.  Expression of laminin alpha1, alpha2, alpha4, and alpha5 chains, fibronectin, and tenascin-C in skeletal muscle of dystrophic 129ReJ dy/dy mice.

Authors:  B Ringelmann; C Röder; R Hallmann; M Maley; M Davies; M Grounds; L Sorokin
Journal:  Exp Cell Res       Date:  1999-01-10       Impact factor: 3.905

10.  Merosin and laminin in myogenesis; specific requirement for merosin in myotube stability and survival.

Authors:  P H Vachon; F Loechel; H Xu; U M Wewer; E Engvall
Journal:  J Cell Biol       Date:  1996-09       Impact factor: 10.539

View more
  7 in total

Review 1.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

2.  Bcl-2 inhibits the innate immune response during early pathogenesis of murine congenital muscular dystrophy.

Authors:  Sheila Jeudy; Katherine E Wardrop; Amy Alessi; Janice A Dominov
Journal:  PLoS One       Date:  2011-08-05       Impact factor: 3.240

3.  Deletion of integrin α7 subunit does not aggravate the phenotype of laminin α2 chain-deficient mice.

Authors:  Kinga I Gawlik; Madeleine Durbeej
Journal:  Sci Rep       Date:  2015-09-10       Impact factor: 4.379

Review 4.  A Family of Laminin α2 Chain-Deficient Mouse Mutants: Advancing the Research on LAMA2-CMD.

Authors:  Kinga I Gawlik; Madeleine Durbeej
Journal:  Front Mol Neurosci       Date:  2020-04-21       Impact factor: 5.639

5.  Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy.

Authors:  Thomas Mehuron; Ajay Kumar; Lina Duarte; Jenny Yamauchi; Anthony Accorsi; Mahasweta Girgenrath
Journal:  Skelet Muscle       Date:  2014-07-02       Impact factor: 4.912

6.  A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides.

Authors:  Janice A Dominov; Ozgün Uyan; Peter C Sapp; Diane McKenna-Yasek; Babi R R Nallamilli; Madhuri Hegde; Robert H Brown
Journal:  Ann Clin Transl Neurol       Date:  2014-09-27       Impact factor: 4.511

7.  Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.

Authors:  Kinga I Gawlik; Johan Holmberg; Martina Svensson; Mikaela Einerborg; Bernardo M S Oliveira; Tomas Deierborg; Madeleine Durbeej
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.